Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


22.01.2024

4 BJU Int
1 BMC Cancer
2 Clin Cancer Res
1 Discov Oncol
4 Eur J Radiol
1 Int J Radiat Oncol Biol Phys
1 J Urol
2 Lancet Oncol
1 Nat Rev Endocrinol
1 PLoS One
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. DEARNALEY D, Griffin CL, Silva P, Wilkins A, et al
    International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial.
    BJU Int. 2024;133:179-187.
    PubMed         Abstract available

  2. DE MARIA M, Meneghetti I, Mosillo L, Collins JW, et al
    Versius robotic surgical system: case series of 18 robot-assisted radical prostatectomies.
    BJU Int. 2024;133:197-205.
    PubMed         Abstract available

  3. TALWAR R, Akinsola O, Penson DF
    What is cancer? A focus on Grade Group 1 prostate cancer.
    BJU Int. 2024 Jan 16. doi: 10.1111/bju.16280.
    PubMed         Abstract available

  4. BESIROGLU H
    Re: 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
    BJU Int. 2024 Jan 18. doi: 10.1111/bju.16277.
    PubMed        


    BMC Cancer

  5. WANG J, Liu J, Yuan C, Yang B, et al
    Palmitic acid-activated GPRs/KLF7/CCL2 pathway is involved in the crosstalk between bone marrow adipocytes and prostate cancer.
    BMC Cancer. 2024;24:75.
    PubMed         Abstract available


    Clin Cancer Res

  6. HALABI S, Guo S, Park JJ, Nanus DM, et al
    The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-3017.
    PubMed         Abstract available

  7. ABIDA W, Hahn AW, Shore N, Agarwal N, et al
    Phase 1 Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing on Enzalutamide.
    Clin Cancer Res. 2024 Jan 16. doi: 10.1158/1078-0432.CCR-23-3508.
    PubMed         Abstract available


    Discov Oncol

  8. ZHANG Y, Huang Y, Dou D
    Anti-prostate cancer mechanism of black ginseng during the "nine steaming and nine sun-drying" process based on HPLC analysis combined with vector space network pharmacology.
    Discov Oncol. 2024;15:12.
    PubMed         Abstract available


    Eur J Radiol

  9. HARTH C, De Vulder N, Hermie L, Vanlangenhove P, et al
    Stereotactic transgluteal prostatic biopsy using Cone-Beam CT navigation and prebiopsy MRI image fusion in a patient without rectal access.
    Eur J Radiol. 2023;170:111265.
    PubMed        

  10. KHAN A, Moore CM, Minhaj Siddiqui M
    Prostate MRI and image quality: The urologist's perspective.
    Eur J Radiol. 2023;170:111255.
    PubMed         Abstract available

  11. WENDEROTT K, Krups J, Luetkens JA, Gambashidze N, et al
    Prospective effects of an artificial intelligence-based computer-aided detection system for prostate imaging on routine workflow and radiologists' outcomes.
    Eur J Radiol. 2023;170:111252.
    PubMed         Abstract available

  12. AGGARWAL P, Singh H, Das CK, Mavuduru RS, et al
    Potential role of (68)Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study.
    Eur J Radiol. 2023;170:111218.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  13. KING MT, Orio PF, D'Amico AV
    Can Extreme Dose Escalation With External Beam Radiation Therapy and Low-Dose-Rate Brachytherapy Boost Obviate the Need for Long-Term Androgen Deprivation Therapy in Patients With High-Risk Localized Prostate Cancer?
    Int J Radiat Oncol Biol Phys. 2024;118:402-403.
    PubMed        


    J Urol

  14. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2024 Jan 15:101097JU0000000000003835. doi: 10.1097/JU.0000000000003835.
    PubMed        


    Lancet Oncol

  15. KAIREMO K
    Targeted alpha therapy: a new tool for advanced prostate cancer.
    Lancet Oncol. 2024 Jan 10:S1470-2045(23)00672.
    PubMed        

  16. SATHEKGE MM, Lawal IO, Bal C, Bruchertseifer F, et al
    Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
    Lancet Oncol. 2024 Jan 10:S1470-2045(23)00638.
    PubMed         Abstract available


    Nat Rev Endocrinol

  17. ANDERSON GM, Hill JW, Kaiser UB, Navarro VM, et al
    Metabolic control of puberty: 60 years in the footsteps of Kennedy and Mitra's seminal work.
    Nat Rev Endocrinol. 2024;20:111-123.
    PubMed         Abstract available


    PLoS One

  18. WESTERBERG M, Irenaeus S, Garmo H, Stattin P, et al
    Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register study.
    PLoS One. 2024;19:e0296804.
    PubMed         Abstract available


    Urology

  19. LANGBEIN BJ, Berk B, Bay C, Tuncali K, et al
    A Phase II Prospective Blinded Trial of MRI and In-Bore Biopsy in Active Surveillance for Prostate Cancer.
    Urology. 2024 Jan 11:S0090-4295(23)01122-6. doi: 10.1016/j.urology.2023.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.